| Carolina Mercy Medical Clinic Pc | |
|
2101 W Franklin Blvd Gastonia NC 28052-1338 | |
| (704) 867-8855 | |
| (704) 867-1414 |
| Full Name | Carolina Mercy Medical Clinic Pc |
|---|---|
| Speciality | Clinic/Center |
| Location | 2101 W Franklin Blvd, Gastonia, North Carolina |
| Authorized Official Name and Position | Cornelius S Okonkwo (DIRECTOR) |
| Authorized Official Contact | 7048678855 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Carolina Mercy Medical Clinic Pc 2101 W Franklin Blvd Gastonia NC 28052-1338 Ph: (704) 867-8855 | Carolina Mercy Medical Clinic Pc 2101 W Franklin Blvd Gastonia NC 28052-1338 Ph: (704) 867-8855 |
| NPI Number | 1104154988 |
|---|---|
| Provider Enumeration Date | 12/07/2009 |
| Last Update Date | 02/05/2010 |
| Medicare PECOS PAC ID | 5395888192 |
|---|---|
| Medicare Enrollment ID | O20100202000492 |
News Archive
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help physicians make better treatment choices for patients with gastric and esophageal adenocarcinoma.
Afraxis, a San Diego-based biotechnology company developing drugs to treat rare genetic diseases through the modulation of p21-activated kinase (PAK), announced today that it has been selected to participate in the National Institutes of Health's (NIH) Therapeutics for Rare and Neglected Disease (TRND) Program.
Investigators at the University of Cincinnati are studying whether or not a modified Atkins-type ketogenic diet could help make treatments for a common, but dangerous, type of brain cancer called glioblastoma more effective.
A number of studies have shown that excess insulin circulating in the bloodstream is a major independent risk factor for cardiovascular disease. However, a new study from Joslin Diabetes Center finds that this condition, called hyperinsulinemia, is itself not a cause of atherosclerosis.
Omeros Corporation today announced that it has secured a committed equity financing facility under which it may sell up to $40 million of its shares of common stock to Azimuth Opportunity, Ltd. over a 24-month period. Omeros is not obligated to use the facility and remains free to enter into and consummate other equity, debt and non-dilutive financing transactions. Omeros intends to use the proceeds from future sales of securities under the facility, if any, for general corporate purposes.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104154988 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QP2300X | Clinic/center - Primary Care | 200100074 (North Carolina) | Primary |
| Provider Name | Cornelius S Okonkwo |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1134235369 PECOS PAC ID: 3678616471 Enrollment ID: I20100202000480 |
News Archive
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help physicians make better treatment choices for patients with gastric and esophageal adenocarcinoma.
Afraxis, a San Diego-based biotechnology company developing drugs to treat rare genetic diseases through the modulation of p21-activated kinase (PAK), announced today that it has been selected to participate in the National Institutes of Health's (NIH) Therapeutics for Rare and Neglected Disease (TRND) Program.
Investigators at the University of Cincinnati are studying whether or not a modified Atkins-type ketogenic diet could help make treatments for a common, but dangerous, type of brain cancer called glioblastoma more effective.
A number of studies have shown that excess insulin circulating in the bloodstream is a major independent risk factor for cardiovascular disease. However, a new study from Joslin Diabetes Center finds that this condition, called hyperinsulinemia, is itself not a cause of atherosclerosis.
Omeros Corporation today announced that it has secured a committed equity financing facility under which it may sell up to $40 million of its shares of common stock to Azimuth Opportunity, Ltd. over a 24-month period. Omeros is not obligated to use the facility and remains free to enter into and consummate other equity, debt and non-dilutive financing transactions. Omeros intends to use the proceeds from future sales of securities under the facility, if any, for general corporate purposes.
› Verified 8 days ago
News Archive
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help physicians make better treatment choices for patients with gastric and esophageal adenocarcinoma.
Afraxis, a San Diego-based biotechnology company developing drugs to treat rare genetic diseases through the modulation of p21-activated kinase (PAK), announced today that it has been selected to participate in the National Institutes of Health's (NIH) Therapeutics for Rare and Neglected Disease (TRND) Program.
Investigators at the University of Cincinnati are studying whether or not a modified Atkins-type ketogenic diet could help make treatments for a common, but dangerous, type of brain cancer called glioblastoma more effective.
A number of studies have shown that excess insulin circulating in the bloodstream is a major independent risk factor for cardiovascular disease. However, a new study from Joslin Diabetes Center finds that this condition, called hyperinsulinemia, is itself not a cause of atherosclerosis.
Omeros Corporation today announced that it has secured a committed equity financing facility under which it may sell up to $40 million of its shares of common stock to Azimuth Opportunity, Ltd. over a 24-month period. Omeros is not obligated to use the facility and remains free to enter into and consummate other equity, debt and non-dilutive financing transactions. Omeros intends to use the proceeds from future sales of securities under the facility, if any, for general corporate purposes.
› Verified 8 days ago
Vance Internal Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3624 Easthampton Dr, Gastonia, NC 28056 Phone: 704-564-1312 Fax: 310-348-0201 | |
Gastonia Medical Specialty Clinic Pa Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1021 X Ray Dr, Gastonia, NC 28054 Phone: 704-867-2341 Fax: 704-867-9019 | |
Gaston Family Health Services, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 137 Stowe Rd, Gastonia, NC 28056 Phone: 704-836-9112 Fax: 704-824-4715 | |
Southern Pulmonary Center, P.a. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 900 Cox Rd, Ste B, Gastonia, NC 28054 Phone: 704-868-3411 Fax: 704-865-9722 | |
Centerwell Senior Primary Care-gastonia Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2910 E Franklin Blvd, 1, Gastonia, NC 28056 Phone: 704-648-0460 Fax: 855-446-7146 | |
Cramerton Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1343 E Garrison Blvd, Ste A, Gastonia, NC 28054 Phone: 704-861-9117 Fax: 704-861-0142 | |
Whitestone Family Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 527 S New Hope Rd, Gastonia, NC 28054 Phone: 704-316-4979 Fax: 704-316-4978 |